Cutting Edge Systemic Treatments: Oral and Biologic
Dr. Egeberg reviews the new oral and biologic treatments in development.
Tuesday, April 25, 2023
Resource Category: Oral Treatments
Considering Comorbidities in Treatment Planning
Dr. Blauvelt discusses the best treatment options for patients with common comorbidities.
Tuesday, April 25, 2023
Current and Novel Treatments
Dr. Rob discusses current psoriasis treatments and why new therapies are still needed.
Tuesday, February 7, 2023
Roflumilast – A Potential New First Line Systemic Drug for Psoriasis
Dr. Zachariae reviews the potential of using Roflumilast as an oral treatment for psoriasis.
Wednesday, November 9, 2022
Focus on Psoriasis: A Report from the 7th Congress of the Skin Inflammation & Psoriasis International Network (SPIN)
Experts worldwide report on their experiences and deliver insight into the latest results and clinical studies. The following congress report
Friday, August 26, 2022
Deucravacitinib: Efficacy and Safety Results from the Phase 3 Trials
In this Take Ten, Dr. Warren provides an update on the phase three trial results for the new oral selective
Friday, February 4, 2022
Network Meta-Analysis – What It Means for Us
Network Meta-Analysis – What It Means for Us Ronald Vender, MD, FRCPC | Canada2021https://www.youtube.com/watch?v=Cqk1pgZiZns
Tuesday, June 22, 2021
The Psoriasis Pipeline: Upcoming New Systemic Drugs
The Psoriasis Pipeline: Upcoming New Systemic Drugs Andrew Blauvelt, MD, MBA | United States 2021
Thursday, January 14, 2021
Safety of Systemic Agents for the Treatment of Pediatric Psoriasis
Safety of Systemic Agents for the Treatment of Pediatric Psoriasis Download PDF
Wednesday, September 13, 2017
